David Eric Strauss - 01 Feb 2025 Form 3 Insider Report for Terns Pharmaceuticals, Inc. (TERN)

Reporting relationship: Principal Accounting Officer
Issuer ticker: TERN
Reported as of: 01 Feb 2025
Net transaction value: $0
SEC form: 3
Accepted by SEC: 11 Feb 2025, 18:06:38 UTC
Source filing: View source filing
Reporting owner signature: /s/ David Strauss

Key filing fact

David Eric Strauss filed Form 3 for Terns Pharmaceuticals, Inc. (TERN) on 11 Feb 2025.

Key facts

This page summarizes David Eric Strauss's Form 3 filing for Terns Pharmaceuticals, Inc. (TERN).
0 reported transactions and 5 derivative rows are listed below.
Accepted by SEC: 11 Feb 2025, 18:06.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TERN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 89,673
Date: 01 Feb 2025
Ownership: Direct
Footnotes: F1, F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TERN holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 01 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,000
Exercise price: $17.00
Footnotes: F4

TERN holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 01 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,250
Exercise price: $10.72
Footnotes: F5

TERN holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 01 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 22,500
Exercise price: $10.43
Footnotes: F6

TERN holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 01 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 33,750
Exercise price: $7.20
Footnotes: F7

TERN holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 01 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 60,000
Exercise price: $6.59
Footnotes: F8

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 8 footnotes

Footnote F1

Includes 2,892 shares represented by a Restricted Stock Unit ("RSU"), of which 25% of the original 11,570 shares subject to the RSUs vested on the first anniversary measured from January 1, 2022 (the "Vesting Commencement Date"), and 1/16th of the total number of shares vested or will vest quarterly thereafter, such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date.

Footnote F2

Includes 15,750 shares represented by a Restricted Stock Unit ("RSU"), of which 25% of the original 31,500 shares subject to the RSUs vested on the first anniversary measured from January 1, 2023 (the "Vesting Commencement Date"), and 1/16th of the total number of shares vested or will vest quarterly thereafter, such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date.

Footnote F3

Includes 12,675 shares represented by a Restricted Stock Unit ("RSU"), of which 25% of the original 16,900 shares subject to the RSUs vested on the first anniversary measured from January 1, 2024 (the "Vesting Commencement Date"), and 1/16th of the total number of shares vested or will vest quarterly thereafter, such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date.

Footnote F4

25% of the shares subject to the option vest on the first anniversary measured from January 25, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.

Footnote F5

25% of the shares subject to the option vest on the first anniversary measured from September 28, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.

Footnote F6

25% of the shares subject to the option vest on the first anniversary measured from January 1, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.

Footnote F7

25% of the shares subject to the option vest on the first anniversary measured from January 1, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.

Footnote F8

25% of the shares subject to the option vest on the first anniversary measured from December 12, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.

SEC remarks

Exhibit 24.1 - Power of Attorney

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .